Last reviewed · How we verify

continuous ropivacaine preperitoneal infusion

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission when infused continuously into the preperitoneal space during and after abdominal surgery.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission when infused continuously into the preperitoneal space during and after abdominal surgery. Used for Postoperative pain management following abdominal surgery, Regional anesthesia via preperitoneal infusion during abdominal procedures.

At a glance

Generic namecontinuous ropivacaine preperitoneal infusion
SponsorAssistance Publique - Hôpitaux de Paris
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhasePhase 3

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve cells, thereby blocking the initiation and conduction of nerve impulses. When delivered via continuous preperitoneal infusion (between the peritoneum and abdominal wall muscles), it provides regional anesthesia and postoperative analgesia to the surgical site, reducing pain and potentially decreasing opioid requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: